Bruton Agammaglobulinemia tyrosine Kinase (BTK) (N-Term) Peptide
Quick Overview for Bruton Agammaglobulinemia tyrosine Kinase (BTK) (N-Term) Peptide (ABIN8095736)
Target
Origin
Source
Application
-
-
Protein Region
- N-Term
-
Purpose
- BTK Peptide - N-terminal region
-
Sequence
- LTVHKLSYYE YDFERGRRGS KKGSIDVEKI TCVETVVPEK NPPPERQIPR
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Comment
-
This is a synthetic peptide designed for use in combination with anti-BTK Antibody (ARP79105_P050),. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 µL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Buffer
- Lyophilized powder
-
Storage
- -20 °C
-
Storage Comment
- For longer periods of storage, store at -20 °C. Avoid repeat freeze-thaw cycles.
-
-
- BTK (Bruton Agammaglobulinemia tyrosine Kinase (BTK))
-
Background
-
Background Information: The protein encoded by this gene plays a crucial role in B-cell development. Mutations in this gene cause X-linked agammaglobulinemia type 1, which is an immunodeficiency characterized by the failure to produce mature B lymphocytes, and associated with a failure of Ig heavy chain rearrangement. Alternative splicing results in multiple transcript variants encoding different isoforms.
Alternative Symbols: AT, ATK, BPK, XLA, IMD1, AGMX1, PSCTK1
-
Molecular Weight
- 53 kDa
-
Gene ID
- 695
-
NCBI Accession
- NP_000052
-
UniProt
- Q5JY90
Target
-
